Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL001 vs Lithium Carbonate in Healthy Adults
NCT06921590Phase 1Completed
- Sponsor
- Alzamend Neuro
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AL001 in bipolar disorder (BD) (2 arms), sponsored by Alzamend Neuro. Primary endpoints: Brain and/or brain structure lithium PK relative to plasma PK at 24 hours, AL001 lithium PK at 24 hours and 1 more. Started May 2025; status: completed.
02
Drugs
AL001
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT06921590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06921590.